Dr. Jean M. Tersak, MD - Pittsburgh, PA ...

Dr. Jean M. Tersak

Claim this profile

Children's Hospital of Pittsburgh of UPMC

Expert in Cancer
Expert in Neuroblastoma
43 reported clinical trials
99 drugs studied

Area of expertise

1Cancer
Global Leader
Jean M. Tersak has run 23 trials for Cancer. Some of their research focus areas include:
Stage I
Stage IV
Stage II
2Neuroblastoma
Global Leader
Jean M. Tersak has run 18 trials for Neuroblastoma. Some of their research focus areas include:
MYC positive
Stage IV
MYC negative

Affiliated Hospitals

Image of trial facility.
Children's Hospital Of Pittsburgh Of UPMC
Image of trial facility.
Children's Hospital Of Pittsburgh

Clinical Trials Jean M. Tersak is currently running

Image of trial facility.

Triptorelin

for Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria

More about Jean M. Tersak

Clinical Trial Related8 years of experience running clinical trials · Led 43 trials as a Principal Investigator · 14 Active Clinical Trials
Treatments Jean M. Tersak has experience with
  • Etoposide
  • Cyclophosphamide
  • Cytology Specimen Collection Procedure
  • Laboratory Biomarker Analysis
  • Carboplatin
  • Doxorubicin Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jean M. Tersak specialize in?
Is Jean M. Tersak currently recruiting for clinical trials?
Are there any treatments that Jean M. Tersak has studied deeply?
What is the best way to schedule an appointment with Jean M. Tersak?
What is the office address of Jean M. Tersak?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security